Hi-NEAT · Hi-NEAT (Hierarchical Nanoengineered Assemblies of Titania) sensor
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2024-09-01 → 2027-05-31
- Финансиране от ЕС
- 222 728 €
- Участници
- 1
- Схема
- HORIZON-TMA-MSCA-PF-EF
Линиите свързват координатора с партньорите.
Накратко на български
Наночастици от титан се използват за създаване на сензор, който открива ензима тирозиназа като маркер за рак на кожата (меланом). Ранното откриване на това заболяване чрез по-бърз и евтин метод помага за навременна диагностика и подобряване на шансовете за оцеляване.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
The proposed research seeks to advance the state of the art in skin cancer diagnostics by developing an electrochemical sensor for tumour markers (or biomarkers) utilizing hierarchical nanoengineered assemblies of titania (Hi-NEAT) nanoparticles. Melanoma is the most aggressive and deadliest form of skin cancer that can spread quickly to other body areas, so its early identification and treatment are vital. The existing histological and immunological cancer detection techniques are intricate, expensive, and often lack sensitivity and specificity. Therefore, in this project, we intend to introduce a subtle, rapid, accurate, facile, and low-cost Hi-NEAT-based electrochemical sensor to detect the biomarker tyrosinase, a crucial enzyme involved in melanin overproduction and development of skin melanoma. The following two research goals have been set forth to achieve this: 1) Creation of Hi-NEAT nanoparticles with enhanced electrocatalytic activity towards tyrosinase via tuning their physicochemical/surface properties and 2) Employing large-scale facilities (synchrotron/neutron sources) to investigate the interfacial properties of the titania-tyrosinase interaction. Thus, the current project represents a groundbreaking approach to push the frontiers of skin cancer diagnosis through the innovative use of titania nanoparticles and large-scale facilities for developing an effective point-of-care electrochemical sensor. Success in this research promises heightened precision and sensitivity in melanoma detection, potentially leading to timely diagnoses and improved patient outcomes. Ultimately, we aspire to make a significant contribution to health care by lessening the severity of melanoma, reducing overall care expenses, and increasing the lifespan of cancer survivors in line with the European Commission’s beating cancer plan.
Оригинален текст от CORDIS (на английски).
Участници
- MALMO UNIVERSITET · MALMOEКоординаторШвеция
Връзки
- Виж в CORDIS
- DOI: 10.3030/101148894
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5193b4612&appId=PPGMS
Данни: CORDIS, © Европейски съюз